knowledge -WSS

knowledge

author：focus 2025-10-02 11:08:10 - browse：25199

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： CommonSpirit Health keeps growing, even as it loses money

focus

WSS

Ukraine and a new approach to mental health in war

Free medical tuition alone isn't enough to close gaps in primary care

CVS is willing to dump 10% of its Medicare Advantage members

How Vertex's cystic fibrosis drug is changing patients' lives

CommonSpirit Health keeps growing, even as it loses money

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

hotspot

knowledge

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Microbiome research is starting to find links to chronic diseases

ChatGPT in medicine: STAT answers readers' burning questions

Biotech stock slump in 2023: awaiting the turnaround

Activists slam private health insurers over coverage restrictions

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Wildfire smoke exposes gaps in outdoor worker protections

Intarcia’s device

Sports medicine is finally prioritizing gender equality

Boston hospital trains restaurant workers on naloxone for overdoses

hotspot

Lasker Awards 2023: Winners in biomedical research

The United States must get value

Supreme Court to hear if Covid misinformation is protected speech

Medical student insurance fails on mental health care coverage

Biotech lab space demand falls sharply

Biotech stock slump in 2023: awaiting the turnaround

hotspot

focus

entertainment

hotspot